Cite
HARVARD Citation
Hillson, J. et al. (n.d.). FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects. Annals of the rheumatic diseases. pp. 495-496. [Online].